Journals / Ege Tıp Dergisi / 2003 / Cilt: 42 - Sayı: 3

KI-67 expression in breast cancer and its relationship with other prognostic factors

Meme kanserinde Kİ-67 ekspresyonu ve diğer prognostik faktörler ile ilişkisi

Pages
173–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The Ki-67 expression is not correlated with lymph node status and patient age.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human breast carcinomas are known to exhibit a broad spectrum of clinical behavior.
📊
Key Findings & Data:The proliferative activity, expression of c-erbB-2 oncoprotein, steroid receptors status, p53 expression and patient age are other important prognostic factors.
💡
Conclusion & Impact:The Ki-67 expression is not correlated with lymph node status and patient age.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Meme neoplazmları · Ki-67 antijeni · Reseptörler

Abstract

Human breast carcinomas are known to exhibit a broad spectrum of clinical behavior. Many attempts have been made in the past to establish reliable and reproducible prognostic parameters. Lymph node involvement, tumor grading and tumor size are accepted as the most important prognostic factors. The proliferative activity, expression of c-erbB-2 oncoprotein, steroid receptors status, p53 expression and patient age are other important prognostic factors. The use of the monoclonal antibody Ki-67 represents an easy and reliable means of assesing cell proliferation. The association between Ki-67 immunoreactivity and other prognostic variables was invastigated in 140 patient with primary breast carcinomas, lmmunohistochemical procedure performed to determine Ki-67, estrogen receptor and c-erbB-2 expression in all cases. Ki-67, c-erbB-2 and estrogen receptor (ER) expression, lymph node positivity in the samples was % 64, % 71, % 34 and % 74, respectively. The chi-square P values are shown for the associations of Ki-67, c-erbB-2 and ER expression. The Ki-67 expression is not correlated with lymph node status and patient age.

Özet

İnsan meme kanserlerinin klinik seyrinin çeşitli şekillerde ortaya çıktığı bilinmektedir. Geçmişte güvenilir ve tekrarlanabilir Prognostik göstergeleri tanımlamak için çok çaba harcanmıştır. Lenf nodu tutulumu, tümör derecesi ve tümör çapı en önemli prognostik faktörler olarak kabul edilir. Diğer önemli prognostik faktörler proliferatif aktivite, c-erbB-2 onkoprotein ekspresyonu, steroid reseptör durumu, p53 ekspresyonu ve hastanın yaşıdır. Hücre proliferasyonunun değerlendirilmesinde Ki-67 monoklonal antikorunun kullanılması, kolay ve güvenilir bir yöntem olarak gösterilmektedir. Ki-67 ekspresyonu ve diğer prognostik değişkenler arasındaki ilişki, primer meme kanserli 140 hastada araştırıldı. Bütün hastalarda Ki-67, östrojen reseptörü ve c-erbB-2 ekspresyonunu belirlemek için immunohistokimyasal yöntem kullanıldı. Ki-67, c-erbB-2 ve östrojen reseptör (ER) ekspresyonu, lenf nodu pozitifliği sırası ile % 64, % 71, %34ve% 74 bulundu. Ki-kare P değerleri; Ki-67, c-erbB-2 ve ER ekspresyonu arasında ilişki olduğunu gösterdi. Ki-67 ekspresyonu, lenf nodu durumu ve hastanın yaşı ile ilişkili değildi.

🔖

Cite This Article

SEZGİN, V. C., KARABULUT, B., ŞANLI, U. A., USLU, R., GÖKER, E., SANAL, S., ÖZDEMİR, N. (2003). KI-67 expression in breast cancer and its relationship with other prognostic factors. Ege Tıp Dergisi, Cilt: 42 - Sayı: 3, 173–177. https://ajindex.com/articles/223013

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Fisher ER, Costantino J, Fisher B, et al. Pathologic finding from the National Surgical Adjuvant Breast Project (protocol 4): Discriminants for 15-year survival. Cancer 1993; 71: 2141-2150
  2. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-1251
  3. Rosner D, Lane WW. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 1991; 68: 1482-1494
  4. Fisher ER, Redmond C, Fisher B, et al. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Natl Cancer Inst Monogr 1992; 11: 151 -158
  5. McQuire WL, Tandon AK, Allred DC, et al. Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr 1992; 11: 173-180
  6. Adami HO, Malker B, Holmbert L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315:559-563
  7. Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer 1986; 57: 2217-2221
  8. Harris AL, Nicholson S, Sainsburgy R, et al. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 1992; 11: 181-187
  9. Foekens JA, van Putten WL, Prtengen H, et al. Prognostic value of PS2 and cathepsin-D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 1993; 11: 899-908
  10. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206
  11. Dressier LG, Eudey L, Gray R, et al. Prognostic potential of DNA flow cytometry measurements in node-negative breast*cancer patients: Preliminary analysis of an intergroup study (INT-0076). J Natl Cancer Inst Monogr 1992; 11:167-172
  12. Nixon AJ, Neuberg D, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 888
  13. Albain KS, Allred KC, et al. Breast cancer outcome and predictors of outcome: are there age differentials? J1 Natl Cancer Inst Monogr 1994; 16: 35
  14. King C, Kraus M, Aaronson S. Amplification of a novel v-erbB-2 related gene in human mammary carcinoma. Science 1985; 229: 974-976
  15. Slamon DJ, Clark GM, Wong SG